Skip to main content

Table 1 Patient, tumor and treatment characteristics

From: Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer

 n%N
médiane[min-max]
Center  91
CFB1617.6% 
CLB4044% 
ICL2830.8% 
IGR77.7% 
Age63.43[42.39–87.34]91
Gender  91
F3336.3% 
M5863.7% 
PS  90
03943.3% 
14347.8% 
288.9% 
Smoker (current or former)7385.9%85
Respiratory comorbidity2629.2%89
Cardiovascular comorbidity2427.3%88
Other cancer history1921.6%88
Other significant comorbidity2123.9%88
Histology  91
Adenocarcinoma5964.8% 
Squamous cell1617.6% 
Small Cell Lung Cancer88.8% 
Other88.8% 
 Molecular alteration1819.8%91
EGFR89% 
ALK22.2% 
KRAS44.5% 
HER222.3% 
cMET amplification11.1% 
cMET mutation11.1% 
T  89
T11820.2% 
T23539.3% 
T32528.1% 
T41112.4% 
N  89
N03134.8% 
N11618% 
N22629.2% 
N31415.7% 
Nx22.2% 
 Pre-therapeutic PET-TDM7987.8%90
Metastase(s) operability  91
Yes77.7% 
No4145.1% 
Not reported4347.3% 
Controlled primitive lesion7784.6%91
Number of metastase(s)  91
18391.2% 
> = 288.8% 
Characteristics of metastatic evolution  91
Metachronous6369.2% 
Synchronous2830.8% 
Indication  91
Oligopersistance1819.8% 
Oligometastatic1011% 
Oligoprogression1819.8% 
Oligorecurrence4549.5% 
Treated site  99
Liver1212.1% 
Lymph node77.1% 
Bone2020.2% 
Lung2121.2% 
Spine1212.1% 
Adrenal2727.3% 
Contralateral to primitive lesion1348.1%27
Homolateral to primitive lesion1451.9%27
Ongoing systemic treatment before irradiation91
No5863.7% 
Yes3336.3% 
Systemic treatment interruption during irradiation 33
No12.9% 
Yes3297.1% 
  1. CFB Centre François Baclesse, CLB Centre Léon Bérard, ICL Institut de Cancérologie de Lorraine, IGR Institut Gustave Roussy